Belly Fat That Won't Go Away

Reviewed by Dr. Farhan Abdullah, DO

Board-Certified Internal Medicine · IFM Certified Functional Medicine Practitioner

Last clinically reviewed · May 2026

Visceral fat is different from love handles

The fat you can pinch — subcutaneous fat — responds reasonably well to caloric restriction and exercise. The fat that lives between and inside your abdominal organs — visceral fat — is much more metabolically aggressive and much more resistant to standard diet-and-exercise. Visceral fat secretes inflammatory cytokines, drives insulin resistance, and creates the characteristic 'fit-with-a-belly' pattern many middle-aged men describe.

Why your testosterone level affects visceral fat directly

Low testosterone is tightly correlated with increased visceral adiposity in men, and the relationship is causal in both directions: low T drives visceral fat accumulation, and visceral fat (via aromatase activity) lowers testosterone further. Breaking this loop requires direct hormone optimization. TRT is often the first lever we pull when visceral fat is the chief complaint and testosterone is genuinely low.

Why GLP-1 works specifically for this pattern

GLP-1 receptor agonists preferentially mobilize visceral fat. Tirzepatide in particular has shown disproportionate visceral fat reduction compared to subcutaneous fat in published trials. For men carrying mostly visceral adiposity, this is the right pharmacologic tool. Combined with TRT, the body composition outcome is significantly better than either alone.

What about peptides for visceral fat?

Tesamorelin — an FDA-approved GHRH analog originally indicated for HIV-associated lipodystrophy — has the strongest peer-reviewed evidence among growth-hormone-axis peptides for visceral fat reduction in non-HIV populations with metabolic syndrome. We prescribe it selectively when visceral adiposity is the primary clinical target and other tools have plateaued.